An anthrax-based treatment holds promise against this difficult-to-treat malignancy.

Those with bladder, larynx, prostate, womb, bowel and breast cancers have the highest rate of death related to cardiovascular disease.

A consortium of health providers and researchers hopes to raise public awareness of how exercise can benefit those living with cancer.

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

The cancer is particularly difficult to treat with traditional therapies.

New results confirm that the drug, Balversa (erdafitinib), can benefit people whose tumors have a certain genetic alteration.

The cancer is particularly difficult to treat with traditional therapies.

“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.

More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.